Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation

Diabetologia

Volumn 61, Issue 3, 2018, Pages 722-726

  Uthman, Laween ^a   Baartscheer, Antonius ^a   Bleijlevens, Boris ^a   Schumacher, Cees A ^a   Fiolet, Jan W T ^a   Koeman, Anneke ^a   Jancev, Milena ^a   Hollmann, Markus W ^a   Weber, Nina C ^a   Coronel, Ruben ^a   Zuurbier, Coert J ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Cardiac; Diabetes; Heart failure; Na+ H+ exchanger; SGLT2i; Sodium; Vasodilation

Indexed keywords

ADENOSINE TRIPHOSPHATE; CANAGLIFLOZIN; CREATINE PHOSPHATE; DAPAGLIFLOZIN; EMPAGLIFLOZIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SODIUM ION; SODIUM PROTON EXCHANGE PROTEIN; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; AMINOPYRIDINE DERIVATIVE; BENZHYDRYL DERIVATIVE; GLUCOSIDE; N-ETHYL-2-((6-METHOXY-PYRIDIN-3-YL)-(TOLUENE-2-SULPHONYL)AMINO)-N-PYRIDIN-3-YLMETHYL-ACETAMIDE; SODIUM; SODIUM GLUCOSE COTRANSPORTER 2; SULFONAMIDE;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING SITE; CARDIAC MUSCLE CELL; CARDIOVASCULAR FUNCTION; CONTROLLED STUDY; CYTOSOL; DRUG EFFECT; ENERGY TRANSFER; ENZYME ACTIVITY; HEART HEMODYNAMICS; HEART MUSCLE METABOLISM; ISOLATED HEART; MOLECULAR DOCKING; MOUSE; NONHUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; STRUCTURAL MODEL; VASODILATATION; ANIMAL; ANTAGONISTS AND INHIBITORS; MALE; METABOLISM;

AMINOPYRIDINES; ANIMALS; BENZHYDRYL COMPOUNDS; CANAGLIFLOZIN; CYTOSOL; GLUCOSIDES; MALE; MICE; MYOCYTES, CARDIAC; SODIUM; SODIUM-GLUCOSE TRANSPORTER 2; SODIUM-HYDROGEN EXCHANGERS; SULFONAMIDES;

EID: 85035777138     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-017-4509-7     Document Type: Article

References (19)

1. Reddy RPM, Inzucchi SE (2016) SGLT2 inhibitors in the management of type 2 diabetes. Endocrine 53:364–372
2. Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128
3. Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644–657
4. + exchanger in rats and rabbits. Diabetologia 60:568–573
5. + exchanger activity and expression in human ventricular myocardium. J Am Coll Cardiol 36:534–540
6. i and underlies disturbed calcium handling in the rabbit pressure and volume overload heart failure model. Cardiovasc Res 57:1015–1024
7. + concentration is elevated in heart failure but Na/K pump function is unchanged. Circulation 105:2543–2548
8. + exchanger contributes to left ventricular hypertrophy in the Goto–Kakizaki rat model of type 2 diabetes: critical role of Akt. Diabetologia 50:1335–1344
9. +-glucose cotransport. J Am Heart Assoc 4:e002183
10. Scheen AJ (2014) Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations. Expert Opin Drug Metab Toxicol 10:647–663
11. Trott O, Olson A (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J Comput Chem 31:455–461
12. Pogwizd SM, Sipido KR, Verdonck F, Bers DM (2003) Intracellular Na in animal models of hypertrophy and heart failure: contractile function and arrhythmogenesis. Cardiovasc Res 57:887–896
13. Karmazyn M (2013) NHE-1: still a viable therapeutic target. J Mol Cell Cardiol 61:77–82
14. +-exchanger causes regression of hypertrophy, heart failure, and ionic and electrophysiological remodeling. Br J Pharmacol 154:1266–1275
15. Lacroix J, Poët M, Maehrel C, Counillon L (2004) A mechanism for the activation of the Na/H exchanger NHE-1 by cytoplasmic acidification and mitogens. EMBO Rep 5:91–96
16. Oelze M, Kröller-Schön S, Welschof P et al (2014) The sodium–glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity. PLoS One 9:1–13
17. Salim HM, Fukuda D, Yagi S, Soeki T, Shimabukuro M, Sata M (2016) Glycemic control with ipragliflozin, a novel selective SGLT2 inhibitor, ameliorated endothelial dysfunction in streptozotocin-induced diabetic mouse. Front Cardiovasc Med 3:1–9
18. + exchanger is required for hyperglycaemia-induced endothelial dysfunction via calcium-dependent calpain. Cardiovasc Res 80:255–262
19. Abdurrachim D, Manders E, Nicolay K, Prompers J, Mayoux E (2017) The effect of a single dose of empagliflozin on cardiac energy status in diabetic mice. Diabetes 66:A125